Please login to the form below

Not currently logged in
Email:
Password:

Shire and TAP in joint sales drive

Specialty biopharmaceuticals company Shire announced on March 26 a joint sales agreement to promote its drug Lialda (mesalamine) in the US
Specialty biopharmaceuticals company Shire announced on March 26 a joint sales agreement to promote its drug Lialda (mesalamine) in the US.

The three-year agreement has been made with TAP Pharmaceutical Products based in Philadelphia in the US to increase sales of Lialda.

Lialda has been developed for use as a once daily oral formulation indicated for the induction of remission in patients with active mild to moderate ulcerative colitis.

Mike Yasick, senior vice president of Shire's gastrointestinal business unit, said: "Aligning with TAP, one of the most successful and well-respected GI sales organisations in the industry, is a tremendous benefit for Shire as it will quadruple the Lialda sales force across the United States."

"Shire's GI team has made Lialda the fastest growing brand of mesalamine and with his collaboration we will bolster the frequency of sales calls to our existing base of specialist physicians," he added.

Tim Rudolphi, vice president of TAP's gastroenterology marketing franchise, said: "This connection with Shire is a natural fit for our sales force, and is a win for all involved, especially the patient population who may benefit most."

27th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics